The Experts below are selected from a list of 554481 Experts worldwide ranked by ideXlab platform
Andrzej Grzybowski - One of the best experts on this subject based on the ideXlab platform.
-
off label Use of bevacizumab for wet age related macular degeneration in europe
Graefes Archive for Clinical and Experimental Ophthalmology, 2020Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:To analyse current Off-Label Use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about Off-Label treatment responded to a questionnaire. Answers were obtained from twenty European countries. The Off-Label Use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the Use of Off-Label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for Off-Label therapy mainly remained unanswered. There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or political consensus on the ophthalmic Off-Label Use of bevacizumab.
-
Off-Label Use of bevacizumab for wet age-related macular degeneration in Europe
Graefe's Archive for Clinical and Experimental Ophthalmology, 2019Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:Purpose To analyse current Off-Label Use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. Methods The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about Off-Label treatment responded to a questionnaire. Results Answers were obtained from twenty European countries. The Off-Label Use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the Use of Off-Label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for Off-Label therapy mainly remained unanswered. Conclusions There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or political consensus on the ophthalmic Off-Label Use of bevacizumab.
Øystein Kalsnes Jørstad - One of the best experts on this subject based on the ideXlab platform.
-
off label Use of bevacizumab for wet age related macular degeneration in europe
Graefes Archive for Clinical and Experimental Ophthalmology, 2020Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:To analyse current Off-Label Use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about Off-Label treatment responded to a questionnaire. Answers were obtained from twenty European countries. The Off-Label Use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the Use of Off-Label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for Off-Label therapy mainly remained unanswered. There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or political consensus on the ophthalmic Off-Label Use of bevacizumab.
-
Off-Label Use of bevacizumab for wet age-related macular degeneration in Europe
Graefe's Archive for Clinical and Experimental Ophthalmology, 2019Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:Purpose To analyse current Off-Label Use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. Methods The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about Off-Label treatment responded to a questionnaire. Results Answers were obtained from twenty European countries. The Off-Label Use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the Use of Off-Label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for Off-Label therapy mainly remained unanswered. Conclusions There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or political consensus on the ophthalmic Off-Label Use of bevacizumab.
Tomas Bro - One of the best experts on this subject based on the ideXlab platform.
-
off label Use of bevacizumab for wet age related macular degeneration in europe
Graefes Archive for Clinical and Experimental Ophthalmology, 2020Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:To analyse current Off-Label Use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about Off-Label treatment responded to a questionnaire. Answers were obtained from twenty European countries. The Off-Label Use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the Use of Off-Label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for Off-Label therapy mainly remained unanswered. There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or political consensus on the ophthalmic Off-Label Use of bevacizumab.
-
Off-Label Use of bevacizumab for wet age-related macular degeneration in Europe
Graefe's Archive for Clinical and Experimental Ophthalmology, 2019Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:Purpose To analyse current Off-Label Use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. Methods The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about Off-Label treatment responded to a questionnaire. Results Answers were obtained from twenty European countries. The Off-Label Use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the Use of Off-Label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for Off-Label therapy mainly remained unanswered. Conclusions There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or political consensus on the ophthalmic Off-Label Use of bevacizumab.
C J B Oliveira - One of the best experts on this subject based on the ideXlab platform.
-
off label Use of ceftiofur in one day chicks triggers a short term increase of esbl producing e coli in the gut
PLOS ONE, 2018Co-Authors: Mauro M S Saraiva, Alexandre Lemos De Barros Moreira Filho, Oliveiro Caetano De Freitas Neto, Nubia Michelle Vieira Da Silva, Patricia Emilia Naves Givisiez, Wondwossen A Gebreyes, C J B OliveiraAbstract:This trial was designed to evaluate the Off-Label Use of ceftiofur with Marek’s vaccine in one-day-old broiler chicks, a prophylactic treatment that has been done in some commercial hatcheries, on the emergence of extended-spectrum beta-lactamase producing Escherichia coli (ESBL-E. coli). A total of 168 chicks (Cobb500®) were Used in a completely randomized design. Birds were assigned to two treatments (Marek’s vaccine plus saline vs Marek’s vaccine plus ceftiofur) and six repetitions, with 14 animals each. Cloacal swabs were collected from 1 to 14 days post-hatch. The majority (86%; p<0.0001) of the ESBL-producing isolates harboring blaCTX-M and blaSHV genes originated from animals receiving the antimicrobial. None of the isolates were positive for plasmid-mediated AmpC betalactamase genes (blaACC, blaCMY-2, blaDHA, blaFOX, blaMOX and blaMIR). These findings indicate that the Off-Label Use of ceftiofur with Marek’s vaccine is associated with the short-term increase in ESBL-producing Escherichia coli in the gut of chicks.
-
Off-Label Use of ceftiofur in one-day chicks triggers a short-term increase of ESBL-producing E. coli in the gut
2018Co-Authors: Mauro M S Saraiva, Nubia Michelle Vieira Da Silva, Patricia Emilia Naves Givisiez, Wondwossen A Gebreyes, Alexandre Moreira L. B. Filho, Oliveiro Freitas C. Neto, C J B OliveiraAbstract:This trial was designed to evaluate the Off-Label Use of ceftiofur with Marek’s vaccine in one-day-old broiler chicks, a prophylactic treatment that has been done in some commercial hatcheries, on the emergence of extended-spectrum beta-lactamase producing Escherichia coli (ESBL-E. coli). A total of 168 chicks (Cobb500®) were Used in a completely randomized design. Birds were assigned to two treatments (Marek’s vaccine plus saline vs Marek’s vaccine plus ceftiofur) and six repetitions, with 14 animals each. Cloacal swabs were collected from 1 to 14 days post-hatch. The majority (86%; p
Magdalena Derebecka - One of the best experts on this subject based on the ideXlab platform.
-
off label Use of bevacizumab for wet age related macular degeneration in europe
Graefes Archive for Clinical and Experimental Ophthalmology, 2020Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:To analyse current Off-Label Use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about Off-Label treatment responded to a questionnaire. Answers were obtained from twenty European countries. The Off-Label Use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the Use of Off-Label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for Off-Label therapy mainly remained unanswered. There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or political consensus on the ophthalmic Off-Label Use of bevacizumab.
-
Off-Label Use of bevacizumab for wet age-related macular degeneration in Europe
Graefe's Archive for Clinical and Experimental Ophthalmology, 2019Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:Purpose To analyse current Off-Label Use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. Methods The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about Off-Label treatment responded to a questionnaire. Results Answers were obtained from twenty European countries. The Off-Label Use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the Use of Off-Label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for Off-Label therapy mainly remained unanswered. Conclusions There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or political consensus on the ophthalmic Off-Label Use of bevacizumab.
